Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous hematopoietic stem-cell transplantation (HSCT) resulted in improved outcomes in patients with high-risk relapsed ...

The analysis comes amid a debate set off when CVS Caremark announced that it would allow self-funded insurers to exclude drugs that entered the market above $100,000 per quality-adjusted life year. A ...

Replacing bleomycin with brentuximab vedotin (Adcetris) in the standard treatment regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) significantly improved overall survival (OS) in ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients ...

Please provide your email address to receive an email when new articles are posted on . The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard ...

Because brentuximab vedotin is so effective in the relapsed and refractory setting, there has been a lot of excitement around assessing the treatment earlier in Hodgkin lymphoma, explained Alison J.

Journal Honors Andrew Lane, MD, PhD, As Recipient of the 2012 JCO Young Investigator Award The other new agent, panobinostat, is representative of a new family of drugs, histone deacetylase inhibitors ...

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with ...

− Indicated for use in adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma – − First targeted treatment approved ...

ROCHESTER, Minn. — A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall ...

Brentuximab vedotin (BV) consists of an anti-CD30 monoclonal Ab conjugated to the agent monomethyl auristatin E, which disrupts the microtubule system leading to cell apoptosis. BV was tested in a ...

A study has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of ...